Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study
Adalimumab biosimilars can be considered viable alternatives to Humira for new patients, with comparable effectiveness and safety. However, owing to the higher likelihood of discontinuation, patients who switch from Humira to biosimilars may require closer monitoring and support.
Authors
- Antonio Sahuquillo‐Torralba
- Zenas Z N Yiu (ORCID: https://orcid.org/0000-0002-1831-074X)
- M.Á. Descalzo (ORCID: https://orcid.org/0000-0002-2262-7547)
- Mark Lunt (ORCID: https://orcid.org/0000-0002-2391-5575)
- Duc Binh Phan (ORCID: https://orcid.org/0000-0002-8916-9093)
- I. García‐Doval (ORCID: https://orcid.org/0000-0002-6881-5260)
- Alicia González-Quesada
- É. Sbidian (ORCID: https://orcid.org/0000-0002-1267-5270)
- Mahmoud Zureik (ORCID: https://orcid.org/0000-0002-8393-4217)
- Raquel Rivera (ORCID: https://orcid.org/0000-0002-4604-0724)
- Hugo Jourdain (ORCID: https://orcid.org/0000-0001-8035-7517)
- Richard Bruce Warren (ORCID: https://orcid.org/0000-0002-2918-6481)
Institutions
- Conservatoire National des Arts et Métiers (FR)
- Université Paris-Est Créteil (FR)
- Manchester Academic Health Science Centre (GB)
- University Hospital Complex Of Vigo (ES)
- University of Manchester (GB)
- Hospital Universitari i Politècnic La Fe (ES)
- Manchester University NHS Foundation Trust (GB)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospital Universitario de Gran Canaria Doctor Negrín (ES)
- Hospital Universitario 12 De Octubre (ES)
- Spanish Academy of Dermatology and Venereology (ES)
- Arthritis UK (GB)
- Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail (FR)
- Complexo Hospitalario Universitario A Coruña (ES)
- NIHR Manchester Biomedical Research Centre (GB)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1093/bjd/ljae454
- Citations
- 3
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Boehringer Ingelheim España
- University of Manchester
- Assistance Publique - Hôpitaux de Paris
- Assistance publique-Hôpitaux de Paris
- Almirall
- LEO Pharma
- Bristol-Myers Squibb Canada
- Manchester Biomedical Research Centre
- AbbVie Canada
- Cilag